180 related articles for article (PubMed ID: 22510349)
1. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Kindler HL; Richards DA; Garbo LE; Garon EB; Stephenson JJ; Rocha-Lima CM; Safran H; Chan D; Kocs DM; Galimi F; McGreivy J; Bray SL; Hei Y; Feigal EG; Loh E; Fuchs CS
Ann Oncol; 2012 Nov; 23(11):2834-2842. PubMed ID: 22700995
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
[TBL] [Abstract][Full Text] [Related]
6. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Macaulay VM; Middleton MR; Protheroe AS; Tolcher A; Dieras V; Sessa C; Bahleda R; Blay JY; LoRusso P; Mery-Mignard D; Soria JC
Ann Oncol; 2013 Mar; 24(3):784-91. PubMed ID: 23104723
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F
Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
13. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
15. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Duran I; Hotté SJ; Hirte H; Chen EX; MacLean M; Turner S; Duan L; Pond GR; Lathia C; Walsh S; Wright JJ; Dancey J; Siu LL
Clin Cancer Res; 2007 Aug; 13(16):4849-57. PubMed ID: 17699864
[TBL] [Abstract][Full Text] [Related]
16. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
[TBL] [Abstract][Full Text] [Related]
18. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
19. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
20. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
